These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 14619959)

  • 41. Collocation of androgen receptor gene mutations in prostate cancer.
    Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
    Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence.
    Tilley WD; Buchanan G; Hickey TE; Bentel JM
    Clin Cancer Res; 1996 Feb; 2(2):277-85. PubMed ID: 9816170
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer.
    Narayanan R; Yepuru M; Szafran AT; Szwarc M; Bohl CE; Young NL; Miller DD; Mancini MA; Dalton JT
    Cancer Res; 2010 Jan; 70(2):842-51. PubMed ID: 20068182
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats.
    Funahashi Y; Wang Z; O'Malley KJ; Tyagi P; DeFranco DB; Gingrich JR; Takahashi R; Majima T; Gotoh M; Yoshimura N
    Prostate; 2015 Mar; 75(4):381-9. PubMed ID: 25451715
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PI3 Kinase inhibition on TRAIL-induced apoptosis correlates with androgen-sensitivity and p21 expression in prostate cancer cells.
    Kadowaki Y; Chari NS; Teo AE; Hashi A; Spurgers KB; McDonnell TJ
    Apoptosis; 2011 Jun; 16(6):627-35. PubMed ID: 21437722
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of androgen receptor in prostatic neoplasia versus hyperplasia.
    Husain I; Shukla S; Soni P; Husain N
    J Cancer Res Ther; 2016; 12(1):112-6. PubMed ID: 27072221
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
    Tan J; Sharief Y; Hamil KG; Gregory CW; Zang DY; Sar M; Gumerlock PH; deVere White RW; Pretlow TG; Harris SE; Wilson EM; Mohler JL; French FS
    Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
    Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
    Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.
    Leach DA; Need EF; Toivanen R; Trotta AP; Palethorpe HM; Tamblyn DJ; Kopsaftis T; England GM; Smith E; Drew PA; Pinnock CB; Lee P; Holst J; Risbridger GP; Chopra S; DeFranco DB; Taylor RA; Buchanan G
    Oncotarget; 2015 Jun; 6(18):16135-50. PubMed ID: 25965833
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
    Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
    Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hormone treatment for prostate cancer: current issues and future directions.
    Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.
    Dehm SM; Regan KM; Schmidt LJ; Tindall DJ
    Cancer Res; 2007 Oct; 67(20):10067-77. PubMed ID: 17942941
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
    Lyons LS; Burnstein KL
    Mol Endocrinol; 2006 May; 20(5):1061-72. PubMed ID: 16384856
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines.
    Orio F; Térouanne B; Georget V; Lumbroso S; Avances C; Siatka C; Sultan C
    Mol Cell Endocrinol; 2002 Dec; 198(1-2):105-14. PubMed ID: 12573820
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.
    Terry S; Yang X; Chen MW; Vacherot F; Buttyan R
    J Cell Biochem; 2006 Oct; 99(2):402-10. PubMed ID: 16741972
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.
    Yuan X; Li T; Wang H; Zhang T; Barua M; Borgesi RA; Bubley GJ; Lu ML; Balk SP
    Am J Pathol; 2006 Aug; 169(2):682-96. PubMed ID: 16877366
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells.
    Rahman MM; Miyamoto H; Takatera H; Yeh S; Altuwaijri S; Chang C
    J Biol Chem; 2003 May; 278(22):19619-26. PubMed ID: 12649293
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy.
    Culig Z; Klocker H; Bartsch G; Hobisch A
    Am J Pharmacogenomics; 2001; 1(4):241-9. PubMed ID: 12083956
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways.
    Shah S; Hess-Wilson JK; Webb S; Daly H; Godoy-Tundidor S; Kim J; Boldison J; Daaka Y; Knudsen KE
    Mol Cancer Res; 2008 Sep; 6(9):1507-20. PubMed ID: 18819937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.